# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Dwight D. Eisenhower (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET015-SYN-TD
- Date: 1956-05-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Russell Okonkwo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Seven-month coronary disease review. **S**

## History of present illness

Mr. Eisenhower returns for his seven-month review. He works full time, travels most weeks, and plays golf twice a week, walking the course, without chest pain or breathlessness. The right-sided nosebleed four weeks ago has not recurred after cautery, and he stopped the petroleum jelly after two weeks. He continues every dose of aspirin and ticagrelor. His home blood pressure averages 120/74 and he has lost 1.5 kg since January. **S**

| Element | Detail |
|---|---|
| Interval change | Full activity including golf; no angina |
| Nosebleed | No recurrence since cautery four weeks ago |
| Home blood pressure | Average 120/74 |
| Weight | Down 1.5 kg since January |
| Nitroglycerin use | None |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Good energy; intentional weight loss |
| Ears, nose, mouth, and throat | Negative | No further nosebleeds |
| Cardiovascular | Negative | No chest pain, palpitations, or edema |
| Respiratory | Negative | No breathlessness walking the golf course |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |

5 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Ticagrelor 90 mg oral tablet, one tablet by mouth twice daily **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**
- Lisinopril 10 mg oral tablet, one tablet by mouth daily **S**
- Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/74 mmHg; pulse 58 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 77.4 kg; BMI 24.4 kg/m². All vital signs are synthetic.

PHQ-2: 0. All results are synthetic.

## Change since baseline

- PHQ-2: 1 at baseline, 0 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, tanned from golf |
| Nose | Right anterior septum healed |
| Heart | Regular rhythm; no murmur or gallop |
| Lungs | Clear |
| Extremities | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Coronary artery disease after myocardial infarction, stable** (I25.10). No angina at full activity about seven and a half months after the infarction. **S**
   - Continue aspirin and ticagrelor to the one-year mark, then review.
   - Continue atorvastatin, ezetimibe, metoprolol, and lisinopril.
2. **Essential hypertension** (I10). Blood pressure 122/74 mmHg, at goal. **S**
   - Basic metabolic panel due in July, six months after the last; order given to have it drawn before the one-year review.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure, heart rate, weight and BMI, heart and lungs, edema | Every visit | Completed today | Blood pressure 122/74 mmHg, weight 77.4 kg, BMI 24.4 |
| Medication safety | Dual antiplatelet therapy adherence and bleeding | Every visit | Completed today | Taking all doses; one anterior nosebleed four weeks ago, controlled with cautery, without recurrence |
| Medication safety | Statin, beta-blocker, and ACE inhibitor adherence | Every visit | Completed today | Taking all doses |
| Laboratory | Basic metabolic panel | 1 to 2 weeks after starting or changing an ACE inhibitor, then every 6 months | Due | Due in July; order given to draw before the one-year review |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing therapy, then every 3 to 12 months | Up to date | LDL cholesterol 50 mg/dL in March; next at the one-year review |
| Survey | Depression screen (PHQ-2) | Every visit | Completed today | Score 0 |
| Self-management | Tobacco use | Every visit | Completed today | Abstinent |
| Self-management | Physical activity and diet | Every visit | Completed today | Golf twice a week walking the course; brisk walks on other days |
| Examination | Clinical follow-up visit | Every 4 to 6 months in the first year | Completed today | Next at one year, when the antiplatelet plan changes |

## Goal progress

- Lower LDL cholesterol below 55 mg/dL by the lipid recheck in about two months. Outcome by 1956-03-16: LDL cholesterol 50 mg/dL on atorvastatin and ezetimibe. **S**
- Keep blood pressure below 130/80 mmHg. Outcome by 1956-03-16: Blood pressure 124/76 mmHg on lisinopril 10 mg and metoprolol. **S**
- Return to full-time work and travel by the seven-month review. Outcome by 1956-05-11: Full-time work since late January; travelling again. **S**
- Keep at least 150 minutes a week of moderate exercise after cardiac rehabilitation. Outcome by 1956-05-11: Brisk walking most days and golf twice a week. **S**
- Complete twelve months of dual antiplatelet therapy without major bleeding. In progress; target 1956-09-28. **S**

## Guideline basis

- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025), American College of Cardiology and American Heart Association
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology
- CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026), Aether Forge

## Follow-up

- One-year review in about four and a half months, with a lipid panel and basic metabolic panel. **S**
- Next scheduled visit 1956-09-28: one-year review after myocardial infarction: end of dual antiplatelet therapy. **S**
